Redalpine closes US$250 million fund for European start-ups
The venture capital firm plans to back 15 to 20 start-ups, with robotics and AI for drug discovery among its areas of focus.
Redalpine said it has raised US$250 million for RAC VIII, making it the firm's largest early-stage fund so far. The European technology and science investor intends to concentrate on seed and Series A funding, putting between US$1 million and US$15 million into each investment.
The firm plans to take the lead or share leadership of investment rounds. It expects the fund to support 15 to 20 start-ups, including businesses working on robotics and artificial intelligence for drug discovery. Scientists account for half its investment team.
RAC VIII is 25 per cent larger than RAC VII, its US$200 million predecessor, which closed in 2024. Redalpine said companies backed by RAC VII have subsequently raised more than US$1.1 billion in total funding. Nearly 50 per cent of that fund's portfolio is UK-based.
Established in Zurich in 2006, Redalpine also operates from Berlin, London and Silicon Valley. Its previous investments include Mistral, N26, Basecamp Research and Proxima Fusion.
